Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Ịdị ọcha>98.0% (HPLC) Ụlọ ọrụ etiti Lenvatinib Mesylate
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates nwere ịdị ọcha dị elu
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Aha Chemical | Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate |
Ụdị okwu | Lenvatinib adịghị ọcha 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D |
Nọmba CAS | 205448-66-4 |
Nọmba CAT | RF-PI1970 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C12H10ClNO3 |
Ibu molekụla | 251.67 |
Ebe esi nri | 377.4± 37.0 ℃ |
Njupụta | 1.320±0.06 g/cm3 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Gbanyụọ-Ọcha ruo ntụ ntụ siri ike na-acha odo odo |
1 H NMR Spectrum | Nkwekọrịta na Ọdịdị |
Ụzọ ịdị ọcha / nyocha | > 98.0% (HPLC) |
Ọnwụ na ihicha | <1.00% |
Mgbakọta adịghị ọcha | <2.00% |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ọkara/adịghị ọcha nke Lenvatinib Mesylate (CAS: 857890-39-2) |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) bụ etiti nke Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib bụ ọgwụ cancer thyroid nke Eisai Corporation nke Japan mepụtara (Code: E7080), bụ nke onye na-emechi ọnụ nke tyrosine kinase (RTK) na-egbochi ọnụ ma nwee ike igbochi ọrụ kinase nke vascular endothelial growth factor Receptors R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Lenvatinib nwekwara ike igbochi itinye aka nke RTK ndị ọzọ na angiogenesis pathological, uto tumor, na ọganihu cancer ma e wezụga maka ọrụ cellular ha na-emekarị gụnyere fibroblast growth factor (FGF) ndị na-anabata FGFR1, 2, 3, na 4;ihe nnabata ihe uto nke platelet (PDGFR [alpha]), KIT, na RET.[Ngosipụta]: Lenvatinib dị mma maka ọgwụgwọ ndị ọrịa nke ọrịa cancer thyroid nke nlọghachi azụ mpaghara ma ọ bụ ụdị metastasis, ụdị ọganihu na redioactive iodine-refractory dị iche iche.